ADIAL PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADIAL PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.98M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($13.20M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($5.12M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($12.73M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.42M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.89M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($8.59M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($11.63M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($1.14M) | Feb 19, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.80M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($8.28M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($6.89M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($10.86M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.29M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.93M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($8.24M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($6.99M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($995.3K) | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.62M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.23M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.27M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.95M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.40M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.85M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.97M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $368.5K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $182.1K | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.49M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($6.92M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($6.81M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($11.19M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($11.95M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($7.63M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($6.34M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($2.50M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($494.9K) | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $64.6K | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.67M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $5.04M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $4.74M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $5.73M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.47M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.49M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $7.68M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $4.70M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $34.5K | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $975.9K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $653.1K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $2.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.97M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.51M | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.28M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.07M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $4.08M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $3.28M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $3.51M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $3.99M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $7.14M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $4.44M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | ($997.6K) | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | ($103.5K) | Feb 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $249.0K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $249.0K | Mar 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($89.97M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($82.00M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($68.80M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($63.67M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($50.94M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($31.52M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($20.63M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($12.04M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($404.0K) | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.88M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.75M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $2.83M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $4.00M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.06M | Mar 30, 2023 |
| FY2022 | Dec 31, 2020 | $4.40M | Mar 30, 2023 |
| FY2020 | Dec 31, 2019 | $6.78M | Mar 22, 2021 |
| FY2020 | Dec 31, 2018 | $3.87M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | $18.2K | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $88.0K | Feb 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (11) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (68) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (11) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (68) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.11M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 258,826 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 1.66M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 1.07M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 20.95M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 14.39M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 10.37M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | 6.86M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | 3.27M | Feb 19, 2019 |